[Durable remission of T-cell prolymphocytic leukemia with CLEC16A::IL2 after allogeneic hematopoietic stem cell transplantation]

Haruka Momose,Naoki Kurita,Hidekazu Nishikii,Nozomi Yusa,Kazuaki Yokoyama,Eigo Shimizu,Seiya Imoto,Toru Nanmoku,Yumiko Maruyama,Tatsuhiro Sakamoto,Yasuhisa Yokoyama,Takayasu Kato,Ryota Matsuoka,Naoshi Obara,Mamiko Sakata-Yanagimoto,Shigeru Chiba
DOI: https://doi.org/10.11406/rinketsu.65.35
Abstract:A 64-year-old woman presented with fine motor impairment in both hands. MRI revealed a contrast-enhanced lesion in the medulla oblongata. Lymphoid cells with abnormal blebs were observed and a CD4+/CD8+ double positive (DP) T cell population was detected by flow cytometry (FCM) in the bone marrow (BM) and the peripheral blood (PB). CLEC16A::IL2 fusion gene was identified by whole exome sequencing with DNA prepared from DP T cells. Clonal rearrangement of the T-cell receptor gene and expression of TCL1A protein were detected. This led to a diagnosis of T-cell prolymphocytic leukemia (T-PLL) with central nervous system (CNS) infiltration. Abnormal cells in BM and PB became undetectable on microscopy and FCM, and the CNS lesion disappeared on MRI after second-line therapy with alemtuzumab. Meanwhile, the CLEC16A::IL2 fusion mRNA remained detectable in PB. Allogeneic hematopoietic stem-cell transplantation was performed, and the fusion mRNA has now been undetectable for more than 5 years since transplantation. This is the first report of a T-PLL case with a CLEC16A::IL2 fusion gene.
What problem does this paper attempt to address?